Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

The majority of patients with chronic myeloid leukemia are successfully managed with life-long treatment with tyrosine kinase inhibitors. In patients in chronic phase, other malignancies are among the most common causes of death, raising concerns on the relationship between these deaths and the off-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Gugliotta, Gabriele, Castagnetti, Fausto, Breccia, Massimo, Albano, Francesco, Iurlo, Alessandra, Intermesoli, Tamara, Abruzzese, Elisabetta, Levato, Luciano, D’Adda, Mariella, Pregno, Patrizia, Cavazzini, Francesco, Stagno, Fabio, Martino, Bruno, La Barba, Gaetano, Sorà, Federica, Tiribelli, Mario, Bigazzi, Catia, Binotto, Gianni, Bonifacio, Massimiliano, Caracciolo, Clementina, Soverini, Simona, Foà, Robin, Cavo, Michele, Martinelli, Giovanni, Pane, Fabrizio, Saglio, Giuseppe, Baccarani, Michele, Rosti, Gianantonio
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5685244/
https://ncbi.nlm.nih.gov/pubmed/28572163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.169532
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados